KeyCorp Comments on Innospec’s Q2 2018 Earnings (IOSP)
Innospec (NASDAQ:IOSP) – Stock analysts at KeyCorp upped their Q2 2018 earnings per share (EPS) estimates for shares of Innospec in a report released on Tuesday, May 15th. KeyCorp analyst M. Sison now anticipates that the specialty chemicals company will post earnings of $1.11 per share for the quarter, up from their previous estimate of $1.08. KeyCorp also issued estimates for Innospec’s Q3 2018 earnings at $0.96 EPS and FY2018 earnings at $4.40 EPS.
Innospec (NASDAQ:IOSP) last released its earnings results on Tuesday, May 8th. The specialty chemicals company reported $1.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.11. The firm had revenue of $360.70 million for the quarter, compared to the consensus estimate of $308.90 million. Innospec had a return on equity of 14.91% and a net margin of 4.86%. The company’s revenue for the quarter was up 22.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.
NASDAQ IOSP opened at $75.60 on Friday. The company has a market cap of $1.83 billion, a PE ratio of 16.12 and a beta of 1.03. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.28 and a current ratio of 2.13. Innospec has a fifty-two week low of $74.05 and a fifty-two week high of $75.05.
Institutional investors and hedge funds have recently bought and sold shares of the stock. C M Bidwell & Associates Ltd. purchased a new position in Innospec during the 4th quarter valued at $142,000. UBS Group AG boosted its holdings in Innospec by 69.3% during the 1st quarter. UBS Group AG now owns 2,771 shares of the specialty chemicals company’s stock valued at $190,000 after acquiring an additional 1,134 shares during the period. Xact Kapitalforvaltning AB purchased a new position in Innospec during the 4th quarter valued at $222,000. Boston Private Wealth LLC purchased a new position in Innospec during the 1st quarter valued at $220,000. Finally, Amalgamated Bank purchased a new position in Innospec during the 4th quarter valued at $245,000. Institutional investors own 89.35% of the company’s stock.
In related news, VP Philip John Boon sold 501 shares of the business’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $67.04, for a total transaction of $33,587.04. Following the completion of the transaction, the vice president now owns 35,439 shares in the company, valued at approximately $2,375,830.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Philip Curran sold 2,000 shares of the business’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $73.63, for a total value of $147,260.00. Following the transaction, the insider now owns 4,218 shares of the company’s stock, valued at approximately $310,571.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,112 shares of company stock valued at $979,984. 2.02% of the stock is owned by company insiders.
The firm also recently disclosed a semiannual dividend, which will be paid on Thursday, May 31st. Investors of record on Monday, May 21st will be issued a dividend of $0.44 per share. The ex-dividend date is Friday, May 18th. This represents a yield of 1.18%. This is a boost from Innospec’s previous semiannual dividend of $0.39. Innospec’s payout ratio is presently 16.74%.
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals for use as fuel additives, ingredients for personal care, home care, agrochemical, mining and other applications, and oilfield chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.